Maternal and Child Care Union, Tbilisi, Georgia.
Trop Med Int Health. 2011 Feb;16(2):186-92. doi: 10.1111/j.1365-3156.2010.02694.x. Epub 2010 Dec 8.
The number of relapses in patients treated for visceral leishmaniasis (VL) has increased, thus identifying prognostic factors may aid decisions on treatment. Demographic and clinical information was abstracted from medical records of patients diagnosed and treated in Georgia from 2002 to 2004. The 300 persons with VL were primarily children <5 years (73.3%), and ∼44% had delays in diagnosis of more than 30 days from symptom onset. All patients received standard therapy with pentavalent antimony (20 mg/kg/day), most for 20-25 days. Factors significantly associated with VL relapse were delay in diagnosis for >90 days (RR = 4.21, 95% CI: 1.58, 11.16), haemoglobin level <60 g/l (RR = 11.96, 95% CI: 4.12, 34.76) and age <1 year (RR = 2.36, 95% CI: 0.96, 5.80). Physician and public education is needed to reduce delays in diagnosis. Prolonging treatment for 30 days (e.g. WHO recommendation) or implementing new regimens may reduce the number of relapses.
接受内脏利什曼病 (VL) 治疗的患者复发人数有所增加,因此确定预后因素可能有助于治疗决策。从 2002 年至 2004 年在格鲁吉亚诊断和治疗的患者的病历中提取了人口统计学和临床信息。300 名 VL 患者主要为 5 岁以下儿童(73.3%),约 44%的患者从出现症状到确诊的时间延迟超过 30 天。所有患者均接受五价锑(20mg/kg/天)标准治疗,大多数患者接受 20-25 天的治疗。与 VL 复发显著相关的因素包括诊断延迟超过 90 天(RR=4.21,95%CI:1.58,11.16)、血红蛋白水平<60g/l(RR=11.96,95%CI:4.12,34.76)和年龄<1 岁(RR=2.36,95%CI:0.96,5.80)。需要对医生和公众进行教育,以减少诊断延误。延长治疗 30 天(例如世界卫生组织的建议)或实施新方案可能会减少复发人数。